247 related articles for article (PubMed ID: 33820494)
21. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
22. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
23. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
24. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
25. Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway Activation.
Lind KT; Chatwin HV; DeSisto J; Coleman P; Sanford B; Donson AM; Davies KD; Willard N; Ewing CA; Knox AJ; Mulcahy Levy JM; Gilani A; Green AL
J Neuropathol Exp Neurol; 2021 Dec; 80(12):1099-1107. PubMed ID: 34850053
[TBL] [Abstract][Full Text] [Related]
26. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
27. Loxo TRK inhibitor data wows oncologists.
Dolgin E
Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
[No Abstract] [Full Text] [Related]
28. Recurrent
Khuong-Quang DA; Brown LM; Wong M; Mayoh C; Sexton-Oates A; Kumar A; Pinese M; Nagabushan S; Lau L; Ludlow LE; Gifford AJ; Rodriguez M; Desai J; Fox SB; Haber M; Ziegler DS; Hansford JR; Marshall GM; Cowley MJ; Ekert PG
Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33144287
[TBL] [Abstract][Full Text] [Related]
29. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
30. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
31. Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma.
Lucas CG; Abdullaev Z; Bruggers CS; Mirchia K; Whipple NS; Alashari MM; Lowichik A; Cheshier S; Phillips JJ; Devine P; Solomon DA; Quezado M; Aldape KD; Perry A
Acta Neuropathol; 2022 Feb; 143(2):283-286. PubMed ID: 34910220
[No Abstract] [Full Text] [Related]
32. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
33. NTRK2 gene fusions are uncommon in pilocytic astrocytoma.
Moreno DA; Becker AP; Scapulatempo-Neto C; Menezes W; Sheren J; Walter AM; Clara C; Machado HR; Oliveira RS; Neder L; Varella-Garcia M; Reis RM
Mol Biol Rep; 2022 Aug; 49(8):7567-7573. PubMed ID: 35713800
[TBL] [Abstract][Full Text] [Related]
34. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
35. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Jones DT; Hutter B; Jäger N; Korshunov A; Kool M; Warnatz HJ; Zichner T; Lambert SR; Ryzhova M; Quang DA; Fontebasso AM; Stütz AM; Hutter S; Zuckermann M; Sturm D; Gronych J; Lasitschka B; Schmidt S; Seker-Cin H; Witt H; Sultan M; Ralser M; Northcott PA; Hovestadt V; Bender S; Pfaff E; Stark S; Faury D; Schwartzentruber J; Majewski J; Weber UD; Zapatka M; Raeder B; Schlesner M; Worth CL; Bartholomae CC; von Kalle C; Imbusch CD; Radomski S; Lawerenz C; van Sluis P; Koster J; Volckmann R; Versteeg R; Lehrach H; Monoranu C; Winkler B; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; Ebinger M; Schuhmann MU; Cho YJ; Pomeroy SL; von Deimling A; Witt O; Taylor MD; Wolf S; Karajannis MA; Eberhart CG; Scheurlen W; Hasselblatt M; Ligon KL; Kieran MW; Korbel JO; Yaspo ML; Brors B; Felsberg J; Reifenberger G; Collins VP; Jabado N; Eils R; Lichter P; Pfister SM;
Nat Genet; 2013 Aug; 45(8):927-32. PubMed ID: 23817572
[TBL] [Abstract][Full Text] [Related]
36. Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW; Hawkins DS
Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
[No Abstract] [Full Text] [Related]
37. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
[TBL] [Abstract][Full Text] [Related]
38. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
39. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
40. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA
Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
